Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Accuredit Therapeutics (Suzhou) Co. Ltd. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This action is distributed across 1 distinct examiner and 1 distinct art unit, showing a consolidated prosecution profile. This concentration suggests that the company's current active filing is focused on a specific innovation that falls within a single technical classification at the patent office, rather than a broad platform technology.
MOHAMMAD Y MEAH is the busiest examiner for this company, managing 1 busiest examiner pending action. As there is only 1 pending office action in total, MEAH handles the entirety of the portfolio's current active workload. The presence of 1 pending office action and 1 distinct examiner suggests a highly specific technical focus for the active application. Practitioners should observe that with 1 distinct examiner and 1 distinct art unit, the prosecution strategy is currently dependent on a single channel of communication and review. This focused interaction within the Biotechnology & Pharmaceuticals sector allows for a dedicated response to the specific requirements of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEAH, MOHAMMAD Y | 1 | 70.8% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835660 | DEAMINASES AND VARIANTS THEREOF FOR USE IN BASE EDITING | MEAH, MOHAMMAD Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835660 | DEAMINASES AND VARIANTS THEREOF FOR USE IN BASE EDITING | MEAH, MOHAMMAD Y | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835660 | DEAMINASES AND VARIANTS THEREOF FOR USE IN BASE EDITING | MEAH, MOHAMMAD Y | 1652 | §102§112 | Non-Final OA | — | Pending | Aug 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial